Follitropin alfa biosimilars: unfounded doubts on the road to reproductive care
Open Access
- 26 July 2025
- journal article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (9) , 1789-1790
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysisHuman Reproduction, 2024
- Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?BioDrugs, 2023
- A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesClinical Pharmacology & Therapeutics, 2022
- Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European RegionsInternational Journal of Molecular Sciences, 2022
- Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsClinical Pharmacology & Therapeutics, 2021
- Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort StudyFrontiers in Endocrinology, 2021
- Streamlined approval of biosimilars: moving on from the confirmatory efficacy trialDrug Discovery Today, 2020
- Evolution of the EU Biosimilar Framework: Past and FutureBioDrugs, 2019
- Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®mAbs, 2016